Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.42 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30750499 | 0.97 | HPGD (0.45) | HPGDGPR119RECQLEPHX1PRMT5 | |
| SCHEMBL13096783 | 0.97 | HPGD (0.47) | HPGDGPR119RECQLEPHX1PRMT5 | |
| SCHEMBL30750751 | 0.93 | GPR119 (0.44) | HPGDGPR119RECQLEPHX1PRMT5 | |
| SCHEMBL4219721 | 0.93 | HPGD (0.48) | HPGDGPR119RECQLEPHX1PRMT5 | |
| SCHEMBL20129275 | 0.92 | HPGD (0.45) | HPGDGPR119RECQLEPHX1PRMT5 | |
| SCHEMBL13107229 | 0.89 | PDE4D (0.47) | HPGDGPR119RECQLEPHX1PRMT5 | |
| SCHEMBL30750720 | 0.88 | HPGD (0.44) | HPGDGPR119RECQLEPHX1PRMT5 | |
| SCHEMBL21458709 | 0.88 | HPGD (0.46) | HPGDGPR119RECQLEPHX1PRMT5 | |
| SCHEMBL21458682 | 0.88 | HPGD (0.46) | HPGDGPR119RECQLEPHX1PRMT5 | |
| SCHEMBL16302472 | 0.88 | HPGD (0.46) | HPGDGPR119RECQLEPHX1PRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| WO-2021011913-A1 | TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2021-01-21 | — | — | WO | disclosed |
| WO-2018102067-A2 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | Arvinas, Inc. (US) | 2018-06-07 | — | — | WO | disclosed |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | MAPT, VHL, CRBN | HPGD 4401/4885GPR119 3791/4885RECQL 1374/4885 |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | CRBN, VHL, UBQLN2 | HPGD 4448/4885GPR119 3741/4885RECQL 1732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.